T2 Biosystems Achieves Second Largest Sepsis-Driven Instrument Sale in Company History, Stocks Surge

LEXINGTON, Mass., May 30, 2023 (GLOBE NEWSWIRE) – T2 Biosystems, Inc. (NASDAQ:TTOO), a renowned player in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, experienced a surge in stock activity today. T2 Biosystems emerged as the most active stock in the market, driven by a significant announcement regarding the company’s latest sales achievement.

The company’s distribution partner, Biomedica Poland, secured a substantial multi-year contract for T2Dx Instruments and sepsis test panels, marking it as the second-largest sale of sepsis-driven T2Dx Instruments in T2 Biosystems’ history. This contract entails the deployment of these instruments in selected hospitals across Poland.

The initial order includes the acquisition of seven T2Dx Instruments, with a total value exceeding $450,000. Furthermore, the contract holds the potential for an additional nine instruments to be sold and deployed in an expanded number of hospitals in Poland throughout the second half of 2023. The agreement’s initial term spans three years, with the possibility of extending it for an additional two years.

T2 Biosystems’ advanced technologies for sepsis detection have gained substantial recognition in the healthcare industry, making it a sought-after solution for hospitals worldwide. This record-breaking sale further solidifies T2 Biosystems’ position as a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes.

Investors responded positively to this news, causing a surge in T2 Biosystems’ stock. The company’s stock price rose significantly, and trading volume reached a notable 156.7 million shares. This surge reflects the market’s confidence in T2 Biosystems’ innovative technology and its potential to address critical healthcare challenges.

As T2 Biosystems continues to make significant strides in the detection of sepsis and antibiotic resistance, the company is well-positioned to drive further growth and deliver impactful solutions for the medical community.

Disclaimer: The information provided in this report is for informational purposes only and should not be considered financial or investment advice. Individuals are encouraged to conduct their own research and consult with a qualified financial advisor before making any investment decisions.